deuterated etoricoxib

**Deuterated etoricoxib** is a deuterium-enriched derivative of etoricoxib, a selective **cyclooxygenase-2 (COX-2)** inhibitor. Deuterium substitution at specific positions enhances metabolic stability compared to non-deuterated etoricoxib while maintaining COX-2 selectivity, potentially improving pharmacokinetics for treating inflammatory conditions. Developed by **Tremeau Pharmaceuticals** as **TRM-362**, it is intended for **acute pain** and retains the mechanism of etoricoxib by inhibiting COX-2 to reduce prostaglandin synthesis from arachidonic acid, with proposed indications including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, gout, and acute pain.[1][6][7][12]

Other names

etoricoxib-d4etoricoxib-d-4etoricoxib-d 4MK-0663-d4MK0663-d4MK 0663-d4